ICER Suggests Price Of $2,500-$8,300 For Biogen’s Aducanumab

Cost Watchdog Sees Insufficient Data To Show Health Benefit

May 06 2021

• By Mandy Jackson

Listen to this article

Given mixed Phase III results for the Alzheimer’s drug and potentially severe side effects for the once-monthly infused therapy, ICER’s recommendation came in below analyst expectations.

The old man leaves the road among the trees. Alzheimer's disease and withdrawal from life. — ICER said aducanumab's benefit in Alzheimer's disease is unclear • Source: Alamy

The Institute for Clinical and Economic Review (ICER) issued a draft evidence report on the effectiveness and value of Biogen, Inc.’s amyloid-clearing antibody aducanumab for mild Alzheimer’s disease with a recommended price of $2,500-$8,300 per year, which fell short of analyst predictions. ICER said the available data for aducanumab are insufficient to determine the net health benefit for patients given mixed Phase III efficacy results and the high risk of a potentially serious side effect.

Opinions of aducanumab’s prospects seem to be largely unchanged by the drug cost watchdog’s assessment, but many observers already have...

More from Drug Pricing

How A New Healthcare Dialogue Is Driving Market Access In Mexico
Nov 06 2025
Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.
India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2
Oct 14 2025
A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.
Sponsored By
Nancy Tests SPARC-931 Part 8
This is a short description. This is a short description.
As More DLL3 Bispecifics Advance, Doctors Are Adjusting To CRS, ICANS
Mar 10 2025
• By Mandy Jackson
Amgen’s Imdelltra for small-cell lung cancer is one of two bispecific T-cell engagers approved for solid tumors, but data at the WCLC meeting show other DLL3-targeting BiTEs may be on the way.

More from Scrip

sponsored
Sponsored by :
Clinical Trial Complexity Is Reshaping Evidence Collection Clinical trial innovation has historical
As clinical trials grow more complex, execution pressures are changing where and how evidence is collected.
EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance
Jul 15 2026
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone
Jun 18 2026
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.